ZVI-NP enhanced anti-tumor immunity via reduction of Treg cells and promotion of M2 macrophages to M1, and repression of PD1 and CTLA4 in CD8+ T cells, as well as reduction of PD-L1 expression in tumor cells. This evidence concerns the gene CTLA4 and neoplasm.